Literature DB >> 30880155

Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription.

Nicholas B Struntz1, Andrew Chen1, Anja Deutzmann2, Robert M Wilson1, Eric Stefan3, Helen L Evans1, Maricela A Ramirez4, Tong Liang4, Francisco Caballero3, Mattheus H E Wildschut3, Dylan V Neel3, David B Freeman5, Marius S Pop5, Marie McConkey6, Sandrine Muller7, Brice H Curtin1, Hanna Tseng3, Kristen R Frombach3, Vincent L Butty8, Stuart S Levine8, Clementine Feau7, Sarah Elmiligy9, Jiyoung A Hong10, Timothy A Lewis7, Amedeo Vetere7, Paul A Clemons7, Scott E Malstrom9, Benjamin L Ebert6, Charles Y Lin11, Dean W Felsher2, Angela N Koehler12.   

Abstract

The transcription factor Max is a basic-helix-loop-helix leucine zipper (bHLHLZ) protein that forms homodimers or interacts with other bHLHLZ proteins, including Myc and Mxd proteins. Among this dynamic network of interactions, the Myc/Max heterodimer has crucial roles in regulating normal cellular processes, but its transcriptional activity is deregulated in a majority of human cancers. Despite this significance, the arsenal of high-quality chemical probes to interrogate these proteins remains limited. We used small molecule microarrays to identify compounds that bind Max in a mechanistically unbiased manner. We discovered the asymmetric polycyclic lactam, KI-MS2-008, which stabilizes the Max homodimer while reducing Myc protein and Myc-regulated transcript levels. KI-MS2-008 also decreases viable cancer cell growth in a Myc-dependent manner and suppresses tumor growth in vivo. This approach demonstrates the feasibility of modulating Max with small molecules and supports altering Max dimerization as an alternative approach to targeting Myc.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Max; Myc; chemical probe; small molecule microarray; transcription

Mesh:

Substances:

Year:  2019        PMID: 30880155     DOI: 10.1016/j.chembiol.2019.02.009

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  30 in total

Review 1.  Transcription Factor Inhibition: Lessons Learned and Emerging Targets.

Authors:  Andrew Chen; Angela N Koehler
Journal:  Trends Mol Med       Date:  2020-02-15       Impact factor: 11.951

2.  MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer.

Authors:  Arnaud Augert; Haritha Mathsyaraja; Ali H Ibrahim; Brian Freie; Michael J Geuenich; Pei-Feng Cheng; Sydney P Alibeckoff; Nan Wu; Joseph B Hiatt; Ryan Basom; Adi Gazdar; Lucas B Sullivan; Robert N Eisenman; David MacPherson
Journal:  Cancer Cell       Date:  2020-05-28       Impact factor: 31.743

Review 3.  Advances in targeting 'undruggable' transcription factors with small molecules.

Authors:  Matthew J Henley; Angela N Koehler
Journal:  Nat Rev Drug Discov       Date:  2021-05-18       Impact factor: 84.694

4.  MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities.

Authors:  Julia Rohrberg; Daniel Van de Mark; Meelad Amouzgar; Joyce V Lee; Moufida Taileb; Alexandra Corella; Seda Kilinc; Jeremy Williams; Marie-Lena Jokisch; Roman Camarda; Sanjeev Balakrishnan; Rama Shankar; Alicia Zhou; Aaron N Chang; Bin Chen; Hope S Rugo; Sophie Dumont; Andrei Goga
Journal:  Cell Rep       Date:  2020-03-10       Impact factor: 9.423

Review 5.  Emerging modes-of-action in drug discovery.

Authors:  Eric Valeur; Frank Narjes; Christian Ottmann; Alleyn T Plowright
Journal:  Medchemcomm       Date:  2019-06-25       Impact factor: 3.597

Review 6.  Multiple roles of HOX proteins in Metastasis: Let me count the ways.

Authors:  Joy Jonkers; Priya Pai; Saraswati Sukumar
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 7.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

8.  Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).

Authors:  Jiang Du; Si Wang; Rui Wang; Si-Yao Wang; Qiang Han; Hong-Tao Xu; Peng Yang; Yang Liu
Journal:  Pathol Oncol Res       Date:  2019-11-22       Impact factor: 3.201

Review 9.  Targeting transcription factors in cancer - from undruggable to reality.

Authors:  John H Bushweller
Journal:  Nat Rev Cancer       Date:  2019-09-11       Impact factor: 60.716

10.  Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC.

Authors:  Lydia Boike; Alexander G Cioffi; Felix C Majewski; Jennifer Co; Nathaniel J Henning; Michael D Jones; Gang Liu; Jeffrey M McKenna; John A Tallarico; Markus Schirle; Daniel K Nomura
Journal:  Cell Chem Biol       Date:  2020-09-22       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.